Heartflow (NASDAQ:HTFL) Insider Sells $380,099.37 in Stock

Posted by Brenda Bartman on Aug 22nd, 2026

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) insider Campbell Rogers sold 9,219 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $41.23, for a total value of $380,099.37. Following the completion of the transaction, the insider owned 86,459 shares of the company’s stock, valued at $3,564,704.57. The trade was a 9.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heartflow Stock Up 6.3%

NASDAQ:HTFL opened at $49.75 on Friday. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $50.48. The company has a market capitalization of $4.33 billion and a P/E ratio of -27.19. The stock’s fifty day moving average is $30.66 and its two-hundred day moving average is $28.32.

Heartflow (NASDAQ:HTFL – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The firm’s revenue was up 47.7% on a year-over-year basis. Sell-side analysts anticipate that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow during the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new position in Heartflow in the 4th quarter valued at approximately $45,000. Legal & General Group Plc purchased a new position in Heartflow in the 3rd quarter valued at approximately $59,000. Essential Partners LLC acquired a new position in shares of Heartflow in the first quarter worth $57,000. Finally, Strs Ohio purchased a new stake in shares of Heartflow during the fourth quarter worth $99,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th. Benchmark restated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. William Blair assumed coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. boosted their target price on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Finally, Freedom Capital upgraded Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Heartflow has a consensus rating of “Moderate Buy” and a consensus target price of $43.43.

Get Our Latest Research Report on HTFL

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.